1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Biohaven’s Degrader Moves Ahead But Pivotal Bipolar Results Depress Shares

 
• By Andrew McConaghie

The company has suffered a setback to its neuroscience asset, BHV-7000, and while its autoimmune disease candidate BHV-1300 is progressing, investors have their doubts.

Biohaven

Biohaven has provided mixed updates from its broad and ambitious pipeline, with solid but unspectacular results from its protein degrader candidate, BHV-1300, and a miss from its ion channel activator, BHV-7000, in a registrational Phase II/III study in bipolar depression.

Both drugs are touted as possible blockbusters in their respective therapy areas, with BHV-7000 being seen as potentially its most...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?